Actively Recruiting
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Led by Janssen Research & Development, LLC · Updated on 2026-05-08
130
Participants Needed
8
Research Sites
136 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) at the putative RP2D(s) (Part 2: Dose Expansion).
CONDITIONS
Official Title
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have B-cell non-Hodgkin lymphoid malignancies with relapsed or refractory disease and no better approved therapies available
- Have received at least 2 prior lines of therapy including an alphaCD20 monoclonal antibody chemotherapy combination
- If received only one prior therapy but not eligible or without access to standard second-line therapies like CAR-T, may enroll
- Agree not to breastfeed, become pregnant, or donate/freeze gametes while on treatment and for 3 months after
- Have an ECOG performance status of 0 to 1
- Have measurable disease as defined by Lugano criteria
- If of childbearing potential, have a negative pregnancy test at screening and before first dose and agree to further testing
You will not qualify if you...
- Have active central nervous system or leptomeningeal involvement
- Have had a prior solid-organ transplant
- Have any other malignancy diagnosis within 1 year before first study dose except certain cured or low-risk cancers
- Have autoimmune or inflammatory disease requiring systemic steroids or immunosuppressive agents within 3 months before first dose
- Have unresolved toxicity from prior cancer therapy above Grade 1 except specified stable conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Peter MacCallum Cancer Centre
Melbourne, Australia, 3000
Actively Recruiting
2
Macquarie University Hospital
North Ryde, Australia, 2109
Actively Recruiting
3
Scientia Clinical Research
Randwick, Australia, 2031
Actively Recruiting
4
UZ Antwerpen
Edegem, Belgium, 2650
Actively Recruiting
5
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
Liège, Belgium, 4000
Actively Recruiting
6
SBU Ankara Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi Faz 1 Merkezi
Ankara, Turkey (Türkiye), 06200
Actively Recruiting
7
Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
Ankara, Turkey (Türkiye), 06620
Actively Recruiting
8
Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi
Istanbul, Turkey (Türkiye), 34010
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here